Zymo Research has entered a strategic partnership with biomodal, integrating biomodal’s “duet” multiomics technology into Zymo’s NGS Services platform. The agreement makes Zymo an authorized provider of biomodal’s evoC and +modC assays, enabling simultaneous analysis of 5-methylcytosine (5mC), 5-hydroxymethylcytosine (5hmC), and standard DNA bases from a single DNA library.
This multi-omic capability is being billed as a major step forward for epigenetics research, since it allows researchers to capture both genetic and regulatory information in one workflow—opening possibilities for deeper insights into gene regulation, disease mechanisms, and cellular function. The service supports a variety of sample types and is backed by Zymo’s full NGS infrastructure, from sample extraction through bioinformatics.
Zymo said the collaboration expands its portfolio and reinforces its reputation as a leader in epigenomics, while biomodal noted that partnering with Zymo strengthens its certified-provider network. The companies expect this combined offering to accelerate research in oncology, neurobiology, aging and precision medicine.
